2 assets in Desmoplastic Infantile Astrocytoma/Ganglioglioma

Therapeutic assets addressing Desmoplastic Infantile Astrocytoma/Ganglioglioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dabrafenib Desmoplastic Infantile Astrocytoma/Ganglioglioma	Novartis Pharmaceuticals	P4	BB (65)
Trametinib Desmoplastic Infantile Astrocytoma/Ganglioglioma	Novartis Pharmaceuticals	P4	BB (65)